FAST Company

Ravel Biotechnology

Ravel Biotechnology is commercializing an analytic technology platform capable of early disease detection from cell-free DNA. Early detection of disease through population level screening has led to decreased mortality and lowered healthcare costs for a set of diseases. The company’s technology enables the accelerated development and validation of screening tests for a wide range of diseases from a single analyte, cell-free DNA. Thus providing the opportunity to screen for a multitude of diseases from a single blood draw.